Duration of treatment: Single dose
Sponsors
Intas Pharmaceuticals Limited, Intas Pharmaceuticals Ltd
Conditions
Health Condition 1: C569- Malignant neoplasm of unspecifiedovaryHealth Condition 1: D693- Immune thrombocytopenic purpura
Phase 1
A study to assess Inj. Romiplostim in patients with Low levels of the blood cells that prevent bleeding
RecruitingCTRI/2017/11/010620
Target: 24Updated: 2021-11-24
A bioequivalence study of a bevacizumab biosimilar in healthy male subjects
Active, not recruitingCTRI/2019/02/017428
Target: 117Updated: 2021-11-24
Unknown Phase
A comparative study of Doxorubicin Hydrochloride (Pegylated Liposomal) in patients with a cancer of female organs that produce eggs
Active, not recruitingCTRI/2018/01/011498
Target: 66Updated: 2021-11-24
A comparative study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) in patients with a cancer of female organs that produce eggs
RecruitingCTRI/2018/01/011550
Target: 66Updated: 2021-11-24